Literature DB >> 15033511

Determination of accurate KI values for tight-binding enzyme inhibitors: an in silico study of experimental error and assay design.

Dennis J Murphy1.   

Abstract

Determination of accurate K(I) values for tight-binding enzyme inhibitors is important from both a basic biochemistry point of view (understanding the differences in affinity of related molecules) and a medicinal chemistry vantage (developing structure-activity relationships (SAR)). It is advantageous to directly fit the quadratic equation describing tight-binding behavior, known commonly as the Morrison equation, to obtain these K(I) values. The results of simulated experiments that examine the effect of assay design and experimental error on the ability to accurately determine K(I) values at several [E]0/K(I-app) ratios are described. Input ("true") values of the uninhibited velocity, inhibition constant, and total enzyme concentration were used to calculate the velocity at various inhibitor concentrations. Gaussian error was introduced into the velocities and the simulated reactions were fit to estimate upsilon0, K(I), and [E]0. Recommendations for optimizing the inhibitor dilutions within the context of a 96-well-plate format and simple serial dilution steps are made. These include using three points to determine the enzyme concentration ([I]=0, 0.5[E]0, and [E]0), using a narrow dilution series with only two or three points to determine the asymptote at high inhibitor concentration, and avoiding fixing [E]0 to a constant value in the fitting if at all possible. The risks and rewards of fixing [E]0 to a constant value, especially the effect on SAR, are also examined.

Mesh:

Substances:

Year:  2004        PMID: 15033511     DOI: 10.1016/j.ab.2003.12.018

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  24 in total

1.  Identification and characterization of beta-lactamase inhibitor protein-II (BLIP-II) interactions with beta-lactamases using phage display.

Authors:  N G Brown; T Palzkill
Journal:  Protein Eng Des Sel       Date:  2010-03-22       Impact factor: 1.650

2.  Fluorometric titration assay of affinity of tight-binding nonfluorescent inhibitor of glutathione S-transferase.

Authors:  Bangtian Xu; Deng Tan; Xiaolan Yang; Xiaolei Hu; Yanling Xie; Jialin Qin; Chunyan Chen; Chenxiong He; Yuanli Li; Jun Pu; Fei Liao
Journal:  J Fluoresc       Date:  2014-10-28       Impact factor: 2.217

3.  Role of β-lactamase residues in a common interface for binding the structurally unrelated inhibitory proteins BLIP and BLIP-II.

Authors:  Bartlomiej G Fryszczyn; Carolyn J Adamski; Nicholas G Brown; Kacie Rice; Wanzhi Huang; Timothy Palzkill
Journal:  Protein Sci       Date:  2014-07-01       Impact factor: 6.725

4.  The Axl kinase domain in complex with a macrocyclic inhibitor offers first structural insights into an active TAM receptor kinase.

Authors:  Ketan S Gajiwala; Neil Grodsky; Ben Bolaños; Junli Feng; RoseAnn Ferre; Sergei Timofeevski; Meirong Xu; Brion W Murray; Ted W Johnson; Al Stewart
Journal:  J Biol Chem       Date:  2017-07-19       Impact factor: 5.157

Review 5.  Mechanistic enzymology in drug discovery: a fresh perspective.

Authors:  Geoffrey A Holdgate; Thomas D Meek; Rachel L Grimley
Journal:  Nat Rev Drug Discov       Date:  2017-12-01       Impact factor: 84.694

6.  Engineering Specificity from Broad to Narrow: Design of a β-Lactamase Inhibitory Protein (BLIP) Variant That Exclusively Binds and Detects KPC β-Lactamase.

Authors:  Dar-Chone Chow; Kacie Rice; Wanzhi Huang; Robert L Atmar; Timothy Palzkill
Journal:  ACS Infect Dis       Date:  2016-10-26       Impact factor: 5.084

7.  Development of an Efficient Enzyme Production and Structure-Based Discovery Platform for BACE1 Inhibitors.

Authors:  Yu-Chen Yen; Annalissa M Kammeyer; Katherine C Jensen; Jagannadharao Tirlangi; Arun K Ghosh; Andrew D Mesecar
Journal:  Biochemistry       Date:  2019-10-22       Impact factor: 3.162

8.  Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors.

Authors:  Michele McTigue; Brion William Murray; Jeffrey H Chen; Ya-Li Deng; James Solowiej; Robert S Kania
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-17       Impact factor: 11.205

9.  Molecular design of a highly selective and strong protein inhibitor against matrix metalloproteinase-2 (MMP-2).

Authors:  Shouichi Higashi; Tomokazu Hirose; Tomoka Takeuchi; Kaoru Miyazaki
Journal:  J Biol Chem       Date:  2013-02-10       Impact factor: 5.157

10.  Mutations Proximal to Sites of Autoproteolysis and the α-Helix That Co-evolve under Drug Pressure Modulate the Autoprocessing and Vitality of HIV-1 Protease.

Authors:  John M Louis; Lalit Deshmukh; Jane M Sayer; Annie Aniana; G Marius Clore
Journal:  Biochemistry       Date:  2015-08-21       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.